114 related articles for article (PubMed ID: 29651974)
1. Preparation and Dosimetry Evaluation of a Carrier- Free 90Y Labeled DOTMP as a Promising Agent for Bone Marrow Ablation.
Salek N; Vosoghi S; Arani SS; Samani AB; Mehrabi M; Maraghe MG
Curr Radiopharm; 2018; 11(2):116-122. PubMed ID: 29651974
[TBL] [Abstract][Full Text] [Related]
2. Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation.
Salek N; Shamsaei M; Ghannadi Maragheh M; Shirvani Arani S; Bahrami Samani A
J Appl Clin Med Phys; 2016 Nov; 17(6):128-139. PubMed ID: 27929488
[TBL] [Abstract][Full Text] [Related]
3. Comparison of systemic toxicities of 177Lu-DOTMP and 153Sm-EDTMP administered intravenously at equivalent skeletal doses to normal dogs.
Bryan JN; Bommarito D; Kim DY; Berent LM; Bryan ME; Lattimer JC; Henry CJ; Engelbrecht H; Ketring A; Cutler C
J Nucl Med Technol; 2009 Mar; 37(1):45-52. PubMed ID: 19223431
[TBL] [Abstract][Full Text] [Related]
4. A preclinical investigation of the saturation and dosimetry of 153Sm-DOTMP as a bone-seeking radiopharmaceutical.
Simón J; Frank RK; Crump DK; Erwin WD; Ueno NT; Wendt RE
Nucl Med Biol; 2012 Aug; 39(6):770-6. PubMed ID: 22459336
[TBL] [Abstract][Full Text] [Related]
5. Estimation of human absorbed dose for (166)Ho-PAM: comparison with (166)Ho-DOTMP and (166)Ho-TTHMP.
Vaez-Tehrani M; Zolghadri S; Yousefnia H; Afarideh H
Br J Radiol; 2016 Oct; 89(1066):20160153. PubMed ID: 27524266
[TBL] [Abstract][Full Text] [Related]
6. 212Bi-DOTMP: an alpha particle emitting bone-seeking agent for targeted radiotherapy.
Hassfjell SP; Bruland OS; Hoff P
Nucl Med Biol; 1997 Apr; 24(3):231-7. PubMed ID: 9228657
[TBL] [Abstract][Full Text] [Related]
7. 177Lu-labeled cyclic polyaminophosphonates as potential agents for bone pain palliation.
Das T; Chakraborty S; Unni PR; Banerjee S; Samuel G; Sarma HD; Venkatesh M; Pillai MR
Appl Radiat Isot; 2002 Aug; 57(2):177-84. PubMed ID: 12150276
[TBL] [Abstract][Full Text] [Related]
8. 166Ho-DOTMP radiation-absorbed dose estimation for skeletal targeted radiotherapy.
Breitz HB; Wendt RE; Stabin MS; Shen S; Erwin WD; Rajendran JG; Eary JF; Durack L; Delpassand E; Martin W; Meredith RF
J Nucl Med; 2006 Mar; 47(3):534-42. PubMed ID: 16513624
[TBL] [Abstract][Full Text] [Related]
9. Feasibility study for production and quality control of Yb-175 as a byproduct of no carrier added Lu-177 preparation for radiolabeling of DOTMP.
Salek N; Shirvani Arani S; Bahrami Samani A; Vosoghi S; Mehrabi M
Australas Phys Eng Sci Med; 2018 Mar; 41(1):69-79. PubMed ID: 29260406
[TBL] [Abstract][Full Text] [Related]
10. Production, biodistribution, and dosimetry of (47)Sc-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetramethylene phosphonic acid as a bone-seeking radiopharmaceutical.
Fathi F; Moghaddam-Banaem L; Shamsaei M; Samani A; Maragheh MG
J Med Phys; 2015; 40(3):156-64. PubMed ID: 26500402
[TBL] [Abstract][Full Text] [Related]
11. A "mix-and-use" approach for formulation of human clinical doses of
Chakraborty S; Vimalnath KV; Rajeswari A; Chakravarty R; Sarma HD; Radhakrishnan E; Kamaleshwaran K; Shinto AS; Dash A
J Labelled Comp Radiopharm; 2017 Jul; 60(9):410-419. PubMed ID: 28477391
[TBL] [Abstract][Full Text] [Related]
12. Use of Monte Carlo simulations with a realistic rat phantom for examining the correlation between hematopoietic system response and red marrow absorbed dose in Brown Norway rats undergoing radionuclide therapy with (177)Lu- and (90)Y-BR96 mAbs.
Larsson E; Ljungberg M; Martensson L; Nilsson R; Tennvall J; Strand SE; Jonsson BA
Med Phys; 2012 Jul; 39(7):4434-43. PubMed ID: 22830776
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies of 177Lu-EDTMP and 177Lu-DOTMP as potential agents for palliative radiotherapy of bone metastasis.
Chakraborty S; Das T; Sarma HD; Venkatesh M; Banerjee S
Appl Radiat Isot; 2008 Sep; 66(9):1196-205. PubMed ID: 18372188
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics, dosimetry and toxicity of holmium-166-DOTMP for bone marrow ablation in multiple myeloma.
Bayouth JE; Macey DJ; Kasi LP; Garlich JR; McMillan K; Dimopoulos MA; Champlin RE
J Nucl Med; 1995 May; 36(5):730-7. PubMed ID: 7738641
[TBL] [Abstract][Full Text] [Related]
15. 90Sr-90Y biokinetics at incorporation determine the radiation burden to bone marrow.
Stevenson AF
Indian J Exp Biol; 2000 Mar; 38(3):222-4. PubMed ID: 10927862
[TBL] [Abstract][Full Text] [Related]
16. Preparation and biological evaluation of 153Sm-DOTMP as a potential agent for bone pain palliation.
Chakraborty S; Das T; Banerjee S; Chaudhari PR; Sarma HD; Venkatesh M; Pillai MR
Nucl Med Commun; 2004 Dec; 25(12):1169-76. PubMed ID: 15640774
[TBL] [Abstract][Full Text] [Related]
17. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu.
Konijnenberg MW; Bijster M; Krenning EP; De Jong M
J Nucl Med; 2004 Jul; 45(7):1260-9. PubMed ID: 15235075
[TBL] [Abstract][Full Text] [Related]
18. Preparation of (166)Dy/(166)Ho-EDTMP: a potential in vivo generator system for bone marrow ablation.
Pedraza-López M; Ferro-Flores G; de Murphy CA; Tendilla JI; Villanueva-Sánchez O
Nucl Med Commun; 2004 Jun; 25(6):615-21. PubMed ID: 15167523
[TBL] [Abstract][Full Text] [Related]
19. Ethylene diamine tetramethylene phosphonic acid labeled with various β(-)-emitting radiometals: labeling optimization and animal biodistribution.
Sohaib M; Ahmad M; Jehangir M; Perveen A
Cancer Biother Radiopharm; 2011 Apr; 26(2):159-64. PubMed ID: 21510750
[TBL] [Abstract][Full Text] [Related]
20. Ce-141-labeled DOTMP: A theranostic option in management of pain due to skeletal metastases.
Vimalnath KV; Rajeswari A; Sarma HD; Dash A; Chakraborty S
J Labelled Comp Radiopharm; 2019 Apr; 62(4):178-189. PubMed ID: 30663098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
